翻訳と辞書 |
Flexion Therapeutics : ウィキペディア英語版 | Flexion Therapeutics
Flexion Therapeutics is an American biotechnology company based in Burlington, Massachusetts that is developing long-lasting intra-articular injection therapies for the treatment of osteoarthritis.〔Gormley, Brian. (28 November 2011). ("Flexion Changes Endgame, Advances Osteoarthritis Drugs." ) Dow Jones VentureWire.〕〔Young, Robin.(8 March 2012).("Could This Be Orthopedics’ Future?" ) Orthopedics This Week.〕 Flexion is developing three new drug candidates: FX005, FX006 and FX007. FX005 is a sustained release, intra-articular p38 mitogen-activated protein kinase (p38 MAP) inhibitor, FX006 is a sustained release, intra-articular steroid, and FX007 is a sustained release, intra-articular TrkA receptor antagonist.〔Jackson, Mandy.(30 May 2012).("Flexion Phase II Data for FX005 gives Clinical PoC in Arthritis Pain." ) SCRIP.〕〔Weintraub, Arlene. (30 May 2012). ("Flexion Overhaul Bears Fruit With Upbeat Data From Arthritis Trial." ) Xconomy.〕〔Gormley, Brian. (30 May 2012). ("Flexion Therapeutics Raises 13M from insiders, Progresses Pipeline." ) Dow Jones VentureWire.〕 == References ==
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Flexion Therapeutics」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|